Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,803 recalls · Class II, newest first

Class II · Moderate risk

Estradiol Cypionate 5 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-639-2013
Class II · Moderate risk

Diazepam 5 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-638-2013
Class II · Moderate risk

Cyclosporine 2% ophthalmic

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-637-2013
Class II · Moderate risk

Cataract drops

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-635-2013
Class II · Moderate risk

Acetylcysteine 2 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-634-2013
Class II · Moderate risk

Acetylcysteine 20 % solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-633-2013
Class II · Moderate risk

Acetylcysteine 10 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-632-2013
Class II · Moderate risk

Donnatal Extentabs

Labeling: Incorrect or Missing Lot and/or Exp Date: Bottled product is labeled with an expiration date of Apr 2015. The correct expiration is Apr 2013.

Terminated Labeling / mix-up West-ward Pharmaceutical Corp. NDC 66213-421-10 D-306-2013
Class II · Moderate risk

Avastin

Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-918-2013
Class II · Moderate risk

Oxiracetam & Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-236-2013
Class II · Moderate risk

BoostYourGrade.com

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-235-2013
Class II · Moderate risk

Brain Defogger

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-234-2013
Class II · Moderate risk

Piracetam & Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-233-2013
Class II · Moderate risk

Aniracetam and Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-232-2013
Class II · Moderate risk

Rifadin

Subpotent drug: low fill volume in some of the capsules

Terminated Wrong potency / content Sanofi US NDC 0068-0510-30 D-841-2013
Class II · Moderate risk

Venlafaxine Hydrochloride Tablets

Failed Tablet/Capsule Specifications: Pharmacist complaint of an excessive amount of broken and/or chipped tablets in the bottle.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-021-01 D-202-2013
Class II · Moderate risk

FREPP/SEPP Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-202-99 D-229-2013
Class II · Moderate risk

Donor Prep Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-201-99 D-228-2013

Recalls by year